Pharmacy Podcast Network - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

Pharmacy Podcast Network — Business
Pharmacy Podcast Network

Pharmacy Podcast Network (PPN) is the world’s largest network of podcasts dedicated to the pharmacy professional and industry insiders. Our content is about dynamic people in the pharmacy industry making a difference and delivering the best pharmacy care. We have over 40+ podcasts with thousands of interviews.

Pharmacists are the cornerstone of healthcare, and the PPN reflects that. From Community, LTC, Specialty Pharmacy to Drug Development, Government policy and DigitalHealth, we cover it all. Partner with us to connect with thousands of daily listeners and find the right pharmacist across various specialties and topics, ensuring your products and services resonate where it matters most. We build strong audio brands through Pharmacists who see patients almost 9x more than primary care.

Join the home of the O.G. Pharmacy Podcast & discover our newest development: Evidence-based Podcasting, the first CME supplement in podcast form that’s truly peer-reviewed. The future of podcasting education for Providers is “Evidence-based Podcasting” (TM) and we’re building a peer-review board, reach out to us: Publisher @ Pharmacy Podcast dot com.

PPN is a division of RxPR, LLC. Copyright 2026

Latest Episodes:

The Inaugural ViVE 2022 Conference in Miami - The Post Conference Show Apr 01, 2022

Show notes

Where there is healthcare for people's lives, Pharmacists must be present. Where were all the Pharmacists at ViVE 2022? The very first ViVE conference was absolutely amazing. ViVE created an immersive environment for interactive learning, idea generation and collaboration for the digital health community to come TogetheRx to advance healthcare. ViVE's inaugural event was on March 6-9, 2022, in Miami Beach, Florida. Where were all the #DigitalHealth Pharmacists? The Pharmacy Podcast Network will work with HLTH and ViVE to assure Pharmacists play a greater role in Tennessee at ViVE 2023. Learn more: https://www.viveevent.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Defining and Supporting the Professional Role of Pharmacists Associated with Traditional and Complementary Medicine Apr 01, 2022

Show notes

Dr. Carolina Ung of University of Macau and Dr. Joanna Harnett are conducting a study to obtain pharmacist opinions on their professional role in complementary medicines. The results of this survey will be used to inform key discussion points in a consensus process and a step towards developing an agreed and defined professional role for pharmacists in traditional and complementary medicines while establishing the support required for pharmacists to enact that role effectively. This is a public health matter implicating the quality and safe use of T&CM. The findings of this international survey contribute to the development of an international consensus regarding: professional role of pharmacists regarding T&CM support required to enact the role effectively and safely More information about the study and a link to the survey can be found here: https://www.surveymonkey.com/r/Ph_T_CM_US_20220316 The study is entirely voluntary and is completed anonymously. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pennsylvanians Suffer while Pharmacy Middlemen Profit | PBM Reform Podcast Series Apr 01, 2022

Show notes

Pennsylvanians suffer while pharmacy middlemen profit By Suzanna Masartis Pennsylvanians are getting crushed by the costs they face at their neighborhood pharmacy counter. The situation has grown so bad that a shocking one in five Keystone State residents report they are unable to take their medications as prescribed due to the cost burden.[1] As a lawmaker and an advocate who speaks to patients in Pennsylvania every day with liver disease, diabetes and other chronic conditions, I am convinced more strongly than ever that we need to reform the prescription drug supply chain. To understand how we got here we need to understand what’s driving increasing costs. A new report found that, in 2020, manufacturers of brand-name and generic medications received only 37 cents of each dollar of the more than $680 billion spent on medications. If you look exclusively at manufacturers of brand-name medications, the drug makers are taking in just under 50 cents on the dollar. So where is the money going? Turns out that it’s little-known middlemen corporations, Pharmacy Benefit Managers (PBMs), that are taking a bigger and bigger share of the pie.[2] PBMs were created to negotiate with insurers and drug manufacturers and establish which prescription drugs are covered by a health plan. In reality, they demand steep discounts from drug makers off of the original list price as a condition to include those drugs on the approved list of medications – and then keep the savings for themselves. But here's the real rip-off: Patients at the pharmacy counter still face co-insurance charges based on the list price -- not the discounted price insurers actually pay. In other words, PBMs are enriching themselves while hiking prices for the rest of us. {3} Worse still, PBMs manipulate their powerful market position to reduce the availability of prescription medications by excluding them from formularies. PBMs make their money when they demand exorbitant rebates from drugmakers and charge patients full cost, meaning they prefer to include drugs with higher list prices on their formulary over an equally effective drug with a lower list price. As a result, a number of drugs are excluded from formularies because PBMs can’t make as much money from them. In 2020, the three largest PBMs excluded 846 FDA-approved drugs, denying patients access to more medications than ever before. This market manipulation has disastrous results for patients. A study published last year found that these practices, called “drug utilization management,” can lead patients to abandon their prescribed medications and delay treatment. Approximately 20% of prescriptions in the U.S. are never filled, according to the study.[4] This outcome is simply unacceptable, and our leaders need to take action. Congress needs to ensure that any attempt to rein in out-of-pocket prescription drug costs includes taking a close and hard look at PBMs. Doing so would go a long way toward ensuring every patient and healthcare consumer in our state can access and afford to take their medications as prescribed by their doctor. Suzanna Masartis of Pittsburgh is the CEO of the Community Liver Alliance. [1]https://www.healthcarevaluehub.org/advocate-resources/publications/pennsylvania-residents-worried-about-high-drug-costs-support-range-government-solutions [2]https://ecommunications.thinkbrg.com/44/2328/uploads/brg-pharmaceutical-supply-chain-2022.pdf?intIaContactId=24HydQaSTYqd85tTztTDcQ%3d%3d&intExternalSystemId=1 [3] https://www.fiercehealthcare.com/payer/study-drug-utilization-costs-health-industry-93b-a-year-patients-bearing-most-cost [4] https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2021.00036 Learn more about your ad choices. Visit megaphone.fm/adchoices

Seizure Clusters: A Review of New Drug Delivery Methods and Emerging Therapy Options | PTCE Pharmacy Connect Mar 31, 2022

Show notes

Educational Objectives Examine challenges in current treatment options for seizure clusters, including efficacy and safety, and differentiating routes of administration Highlight considerations in treatment of seizure clusters, including addressing barriers to treatment and providing patient counseling to improve outcomes Faculty: Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM Professor Departments of Pharmacotherapy & Outcomes Science and Neurosurgery Virginia Commonwealth University, Medical College of Virginia Richmond, Virginia Neurocritical Care Clinical Pharmacist Virginia Commonwealth University Health Richmond, Virginia Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Department of Defense Consultant: UCB, Chiesi, Marinus, Alexion, Ceribell Speakers Bureau: UCB, Chiesi Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-129-H01-P. The activity is available for CE credit through March 31, 2023. This activity is supported by an educational grant from Neurelis Inc. Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM is Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery at Virginia Commonwealth University (VCU) School of Pharmacy, Medical College of Virginia Campus. She is a Past President of the Neurocritical Care Society. Dr. Brophy’s research interests include neuropharmacotherapy, traumatic brain injury, biomarkers, hemostasis, stroke, and status epilepticus. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pittsburgh Pharmacy Business Innovators | RxInfluencers Mar 30, 2022

Show notes

Pittsburgh Headquartered based Pharmacy Podcast Network welcomes 3 Pittsburgh Pharmacy Business Innovators. Todd Eury welcomes Dr. Kyle McCormick to an interesting discussion with fellow pharmacy owners Shawn Nairn and Chris Antypas. Payment model changes, PBM Reform, Cost-plus pricing strategies, and some surprise growth announcements --all part of this dynamic conversation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Successful Nutritional Supplements Business in Your Pharmacy | Pharmacy Crossroads Mar 30, 2022

Show notes

Two accomplished professionals share insights into key things to look for, and to do, have a successful nutritional supplement business in your pharmacy. Dennis Song, R.Ph. and owner of Flower Mound Pharmacy in Flower Mound, Texas is doing remarkable things. Critical to his success, he says, is working closely with prescribers and finding ways for nutraceuticals to become part of their prescribing habits. Getting out of the pharmacy and taking at community events is also a key aspect of success. Mike Ewers, CEO of Medella Springs provides an “insider's” view of the way his company decides which products they can produce that meet a need in the consumer market place and how clinical and functional trials help them produce products that deliver on their promise. At the end of the day, Song says there is a need for pharmacists to get more involved in helping people prevent illness. Learn more about your ad choices. Visit megaphone.fm/adchoices

Novel Non-stimulant ADHD Treatments: A Review for Pharmacists | PTCE Pharmacy Connect Mar 29, 2022

Show notes

Educational Objectives Describe the impact of ADHD and new non-stimulant class of ADHD treatments Highlight the role of the pharmacist in patient counseling, monitoring and medication management in ADHD Faculty: Sandy Mullen, PharmD, BCPP Clinical Pharmacy Specialist - Child and Adolescent Psychiatry Department of Pharmacy Virginia Commonwealth University (VCU) Health Richmond, VA Sandy Mullen, PharmD, BCPP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-127-H01-P. The activity is available for CE credit through March 30, 2023. This activity is supported by an educational grant from Supernus. Learn more about your ad choices. Visit megaphone.fm/adchoices

Digital Health with Bakul Patel | Darshan Talks Mar 28, 2022

Show notes

In this episode of the DarshanTalks Podcast, we have a discussion about Digital Health with Bakul Patel, Director, Digital Health Center of Excellence of US FDA department. He has over 28 years of leadership, business development, marketing, product management, assessing long and short-term needs, establishing objectives, improving organizational performance, and resource management. Expertise in medical device regulations, product development processes, software engineering, embedded systems, wireless communication systems, and robotics and control systems. Masters in Electronics Engineering, MBA in International Business. Six Sigma, Black-belt certified. With all the bucket of knowledge of digital health, the conversation started off with FDA going through massive changes currently. He explains his area of work in the digital health technology sphere and leading digital health with no jurisdiction boundaries, as this sector is wide in nature, and he further explains how it's always been fun to work in such an atmosphere. When it comes down to FDA there are portions of that spectrum of digital health as it may be general wellness. According to the expert, digital health is a spectrum, a continuum, a journey for an individual and purview under FDA's jurisdiction. The focus of the conversation was on the department that the expert works and the people who don't know much about can reach out to the department for advice, suggestions, reviews or portions of review depending on the products that come to different parts of the agency. There are some policy challenges, he emphasised on FDA needs to start evolving that their agency have been actively working on with other parts of the agency. Recent guidance on digital health tech in clinical trials was launched by his department and he described all the related information and implications in this podcast. ---- Disclaimers: 1. This discussion is merely an oral discussion and should not be relied upon solely on its own to support any conclusion of law or fact. 2. The discussion does not and should not reflect any individual products status as safe, efficacious, adulterated, or misbranded or meeting or not meeting expectations at a local, state, federal, or international agency or organization. 3. The discussion should not be construed to be complete advice that is right for you and may not necessarily represent a specific product. 4. This discussion is provided for general educational purposes and should not be construed as legal advice, regulatory advice, or medical advice. 5. This does not create an attorney-client relationship. Learn more about your ad choices. Visit megaphone.fm/adchoices

An Insider Discusses How Government Affairs Work Affects Your Pharmacy | Pharmacy Crossroads Mar 25, 2022

Show notes

If you have ever wondered what government affairs executives do and how they affect the practice of pharmacy then you’ll want to spend 35 minutes listening to this episode. Mark Kinney, a pharmacist, has more spent more than 30 years meeting with elected officials and other influential officials to help them better understand the complex and important role pharmacy owners play in our society. And, as you’ll learn in this podcast, government affairs work goes far beyond PBM and DIR fee battles. Learn more about your ad choices. Visit megaphone.fm/adchoices

Clinical Decision Support Software: A Key Tool for Optimizing Population Health Level Pharmacogenomics Programs | PGx For Pharmacist Mar 24, 2022

Show notes

Episode Description: On this episode, Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences, and I discuss the importance of population health level pharmacogenomics versus one time pharmacogenomics tests and how clinical decision support software that integrates pharmacogenomics data into patients’ medication therapy management is a key tool to optimize population health level pharmacogenomics programs. References: 1. Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program https://www.mdpi.com/2075-4426/12/3/421 2. Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report https://www.cureus.com/articles/81096-idiopathic-symptoms-resolved-by-pharmacogenomics-enriched-comprehensive-medication-management-a-case-report 3. Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry https://www.coriell.com/resources/consequences-of-cyp2d6-copy-number-variation-for-pharmacogenomics-in-psychiatry/ 4. The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978656/ 5. ASP Establishes March 24th as National Adverse Drug Event Awareness Day https://www.stopadr.org/blog/asp-establishes-march-24-as-national-adverse-drug-event-awareness-day-launches-awareness-campaign Guest’s Bio: Jeffrey A. Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences (CLS), an international leader in precision medicine. Leveraging extensive experience in genetics and pharmacology, he is a leading expert in the rapidly evolving field of pharmacogenomics (PGx), the study of how an individual’s DNA impacts his or her response to medication. Most importantly, Dr. Shaman plays a critical role in bridging the gap between genetic science and clinical application. This includes translating decades of cutting-edge genetic research into actionable insights on the safest and most effective medications for individuals based on their unique DNA and dozens of other factors. Driven to advance public health, Dr. Shaman is focused on enabling the delivery of personalized medicine at scale and empowering the most precise medical care worldwide. He consults with large employers, public and private payer organizations, healthcare systems, academic institutions, and laboratories around the globe, advising them on how to eliminate trial-and-error prescribing, improve population health, and control rising healthcare costs Dr. Shaman is dedicated to setting the industry standard for PGx and pioneering new advancements in the field. Along with his team, he actively researches and presents findings in top peer-reviewed journals and at leading industry events. He is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, Personalized Medicine Coalition (PMC), Pharmacogenomics Global Research Network (PGRN), and other organizations. Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology. Dr. Shaman held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Related Podcasts